New York, September 23, 2016 -- Moody's Investors Service (Moody's) today assigned new ratings to BioClinica Holding I, LP, including a B3 Corporate Family Rating (CFR) and B3-PD Probability of Default Rating (PDR). BioClinica Holding I, LP is the parent company of the co-borrowers (BioClinica-Synowledge Holdings Corp., BioClinica-eClinical Holdings, LLC, BioClinica Synarc Corp., BioClinica Clinverse Corp.) and will guarantee the debt. Moody's also assigned a B1 to the senior secured first lien revolver and term loan and a Caa2 to the senior secured second lien term loan. The loan proceeds, together with cash and rollover equity, will be used to fund the planned acquisition of BioClinica by Cinven, a private equity firm, including the repayment of BioClinica's existing debt. The outlook is stable.

Vollständigen Artikel bei Moodys lesen